Takeda Director Yoshiaki Fujimori Reports Initial Holdings
TAKEDA PHARMACEUTICAL CO LTD
Subscribe to track TAK
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Takeda Director Yoshiaki Fujimori Reports Initial Holdings
Company: TAKEDA PHARMACEUTICAL CO LTD (TAK) Form: 3 (Initial Statement of Beneficial Ownership) | Filed: 2026-03-18 Significance: Low
Insider: FUJIMORI YOSHIAKI Relationship: Director
Holdings Reported: • Security: Ordinary Shares • Direct Holdings: 27,865 shares • Derivative/Tax Awards: 9,342 shares (equivalent) • Total Exposure: ~37,207 shares
Key Insight: Director Fujimori files initial statement of beneficial ownership. This is a disclosure of existing holdings upon becoming a reporting person, not a new open market purchase.
Market Context: Transaction represents <0.01% of shares outstanding. Neutral market impact.
Comprehensive Analysis
SEC Filing Analysis: TAKEDA PHARMACEUTICAL CO LTD (TAK)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Director Yoshiaki Fujimori files Form 3 disclosing initial beneficial ownership of approximately 37,207 shares (including derivatives).
- Market Impact: Neutral - This is a regulatory disclosure of existing holdings, not a new trading signal.
Company Information
| Field | Value |
|---|---|
| Company | TAKEDA PHARMACEUTICAL CO LTD |
| Ticker Symbol | TAK |
| CIK | 0001395064 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | FUJIMORI YOSHIAKI |
| CIK | 0001233160 |
| Title/Position | Director |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 3 (Initial Statement) |
| Filing Date | 2026-03-18 |
| Security Type | Ordinary Shares & Tax Obligation Awards |
| Direct Holdings | 27,865 |
| Derivative Holdings | 9,342 (Tax Obligation Awards) |
| Total Ownership | 37,207 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Total Holdings Reported | 37,207 shares |
| % of Shares Outstanding | 0.0023% |
| Market Cap | $8,979.44 billion |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: With a market capitalization of $8,979.44 billion, these holdings are microscopic in value relative to the company size.
- Ownership Concentration: The insider holds approximately 0.0023% of the 1.59 billion shares outstanding, indicating a minor minority position.
- Dilution Impact: No immediate dilution; these are existing awards and holdings being reported.
- Transaction Significance: As a Form 3, this establishes a baseline for future comparisons but does not represent current buying pressure.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The filing is administrative (Form 3) and discloses a relatively small position for a company of this magnitude. It does not signal a shift in sentiment or a material financial commitment at current prices.
Volume & Sentiment
- Expected Volume Impact: Negligible.
- Sentiment Indicator: Neutral.
Additional Context
Transaction Notes
- Derivatives: The reporting person holds "Tax Obligation Awards" vesting between 2026 and 2028, which are cash-settled equivalents to Ordinary Shares.
- RSUs: The direct holdings include 8,400 Restricted Stock Units (RSUs) vesting annually through 2028.
- Insider Background: The insider uses a business address associated with Boston Scientific, suggesting cross-industry board experience.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.